TABLE I.
Demographic and Clinical Characteristics of HIV-1 Infected Participants
| HIV-1 infected participants (n =165) | |
|---|---|
| Males (n, %) | 74 (44.8) |
| Age (median, IQR) | 24 (23.5–25) |
| Current HIV RNA | |
| Undetectable (<=34 copies/ml) | 100 (60.6) |
| 35–1000 copies/ml | 25 (15.2) |
| >1000 copies/ml | 40 (24.2) |
| Zenith HIV RNA log10, copies/ml | 5.06 (4.3–5.6) |
| Nadir CD4 count, cells/mm3 (median, IQR) | 85 (23–183.5) |
| Current CD4 count (n, %) | |
| <350 cells/mm3 | 49 (29.7) |
| >350 cells/mm3 | 116 (70.3) |
| Current CD8 count, cells/mm3(median, IQR) | 743 (535–1015.5) |
| CD4/CD8 ratio (n, %) | |
| Q1 0–25% | 38 (23) |
| Q2 25–50% | 43 (26.1) |
| Q3 50–75% | 40 (24.2) |
| Q4 75–100% | 42 (25.5) |
| Time since HIV diagnosis, years (median, IQR) | 23.98 (22.9–24.7) |
| CDC clinical staging (n, %) | |
| A | 3 (1.8) |
| B | 81 (49.1) |
| C | 81 (49.1) |
| Antiretroviral treatment duration, months (median, IQR) | 143.51 (98.7–173) |
Values are presented as number (%) or median (interquartile range).